Clinical Trials Logo

Peritoneal Carcinoma clinical trials

View clinical trials related to Peritoneal Carcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04498117 Active, not recruiting - Ovarian Cancer Clinical Trials

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

FLORA-5
Start date: August 25, 2020
Phase: Phase 3
Study type: Interventional

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.

NCT ID: NCT03839524 Active, not recruiting - Clinical trials for Fallopian Tube Cancer

A Trial Evaluating TG4050 in Ovarian Carcinoma.

Start date: December 9, 2019
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, single arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.

NCT ID: NCT03732781 Active, not recruiting - Clinical trials for Colorectal Carcinoma

Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC

Start date: May 27, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2a open label study to evaluate the dose, safety, tolerability and efficacy of an IP α-emitting radionuclide therapy (Radspherin®) in subjects with peritoneal carcinomatosis (PC) from colorectal carcinoma following complete CRS (cytoreduction score CC-0) and HIPEC. The study consists of three different cohorts: - Dose escalation cohorts - Repeated injection cohorts - Expansion cohort

NCT ID: NCT03054298 Active, not recruiting - Ovarian Cancer Clinical Trials

CAR T Cells in Mesothelin Expressing Cancers

Start date: April 6, 2017
Phase: Phase 1
Study type: Interventional

Phase I study to establish safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells with or without lymphodepletion.

NCT ID: NCT02125513 Active, not recruiting - Ovarian Cancer Clinical Trials

Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer

GOGER-01
Start date: January 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to define whether 6 courses of neoadjuvant chemotherapy can lead to a higher rate of complete cytoreductive surgery compared with 3 courses of neoadjuvant chemotherapy in patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.